AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28575774 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 83
Study 26262903 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (mean 2.47mg/day, S.D. 1.29mg)
Number of subjects: 84
Study 26262903 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 84
Study 24038561 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg daily
Number of subjects: 30
Study 24038561 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 40 mg daily
Number of subjects: 30
Study 20843236 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4% moxifloxacin gel
Number of subjects: 57
Study 20843236 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25% moxifloxacin gel
Number of subjects: 57
Study 20843236 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.125% moxifloxacin gel
Number of subjects: 57
Study 20843236 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 57
Study 18162659 — intervention group
Group type: EXPERIMENTAL
Intervention: Firsthand experience of a situation
Number of subjects: 0
Study 18162659 — intervention group
Group type: COMPARATOR
Intervention: No firsthand experience of a situation
Number of subjects: 0
Study 18162659 — intervention group
Group type: EXPERIMENTAL
Intervention: Holier-than-thou biases
Number of subjects: 0
Study 16789449 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver coated pins (SC)
Number of subjects: 19
Study 16789449 — intervention group
Group type: COMPARATOR
Intervention: Stainless steel pins (SS)
Number of subjects: 19
Study 15388302 — intervention group
Group type: EXPERIMENTAL
Intervention: Full narration (verbal information during demonstration and test)
Number of subjects: 0
Study 15388302 — intervention group
Group type: COMPARATOR
Intervention: Empty narration (no verbal information)
Number of subjects: 0
Study 15388302 — intervention group
Group type: EXPERIMENTAL
Intervention: Verbal cues only at the time of retrieval
Number of subjects: 0
Study 15388302 — intervention group
Group type: COMPARATOR
Intervention: Verbal cues only at the time of original encoding
Number of subjects: 0
Study 15388302 — intervention group
Group type: COMPARATOR
Intervention: Verbal cues presented only at the time of original encoding
Number of subjects: 0
Study 11303414 — intervention group
Group type: EXPERIMENTAL
Intervention: Emedastine 0.05% twice daily for 42 days
Number of subjects: 221
Study 11303414 — intervention group
Group type: COMPARATOR
Intervention: Levocabastine 0.05% twice daily for 42 days
Number of subjects: 221
Study 9247526 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (800 mg/day for 14 days, 400 mg/day for 50 weeks, then 300 mg/day thereafter)
Number of subjects: 519
Study 9247526 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study 9247526 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (in patients with COPD)
Number of subjects: 519
Study 9247526 — intervention group
Group type: COMPARATOR
Intervention: Placebo (in patients with COPD)
Number of subjects: 519
Study 9247526 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 519
Study 8273226 — intervention group
Group type: EXPERIMENTAL
Intervention: Preincisional lidocaine infiltration (1% lidocaine, 40 ml)
Number of subjects: 37
Study 8273226 — intervention group
Group type: COMPARATOR
Intervention: Postincisional lidocaine infiltration (1% lidocaine, 40 ml)
Number of subjects: 37
Study 3542342 — intervention group
Group type: EXPERIMENTAL
Intervention: L-adrenaline infusion
Number of subjects: 8
Study 3542342 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol infusion
Number of subjects: 8
Study 3542342 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 8
Study 30390699 — intervention group
Group type: EXPERIMENTAL
Intervention: Low protein breakfast (12.4% protein)
Number of subjects: 22
Study 30390699 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium protein breakfast (23.5% protein)
Number of subjects: 22
Study 30390699 — intervention group
Group type: EXPERIMENTAL
Intervention: High protein breakfast (40.6% protein)
Number of subjects: 22
Study 30390699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum meal after breakfast
Number of subjects: 22
Study 27842939 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose baclofen (up to 150mg)
Number of subjects: 151
Study 27842939 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose baclofen (30mg)
Number of subjects: 151
Study 27842939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 24897342 — intervention group
Group type: EXPERIMENTAL
Intervention: Red yeast rice
Number of subjects: 804
Study 24897342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 804
Study 22608583 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Number of subjects: 77
Study 22608583 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg
Number of subjects: 77
Study 22608583 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (both doses)
Number of subjects: 77
Study 20465440 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated applanation tonometry measurements in glaucoma patients
Number of subjects: 67
Study 20465440 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients scheduled for cataract surgery)
Number of subjects: 67
Study 18684280 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed AVD of 60-160 ms during CRT
Number of subjects: 30
Study 16182720 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin supplementation
Number of subjects: 56
Study 16182720 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 56
Study 14716113 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiation
Number of subjects: 50
Study 14716113 — intervention group
Group type: COMPARATOR
Intervention: Radiation treatment (Control)
Number of subjects: 50
Study 11061483 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual counseling by a doctor with a five-month intervention
Number of subjects: 263
Study 11061483 — intervention group
Group type: COMPARATOR
Intervention: Equivalent delayed intervention for four months
Number of subjects: 263
Study 11061483 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall smoking cessation intervention
Number of subjects: 263
Study 11061483 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term survey of those who succeeded in quitting
Number of subjects: 263
Study 8642232 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (5 mg)
Number of subjects: 7
Study 8642232 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalaprilat (2 mg)
Number of subjects: 7
Study 8642232 — intervention group
Group type: COMPARATOR
Intervention: Saline (Control)
Number of subjects: 7
Study 8460795 — intervention group
Group type: COMPARATOR
Intervention: Halothane anaesthesia
Number of subjects: 40
Study 8460795 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anaesthesia
Number of subjects: 40
Study 4027636 — intervention group
Group type: EXPERIMENTAL
Intervention: Helium-neon laser (632.5 nm, 1 mW, 20 Hz)
Number of subjects: 21
Study 4027636 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 21
Study 29654560 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-concentration contrast medium (LC-CM) with iodixanol 270
Number of subjects: 65
Study 29654560 — intervention group
Group type: COMPARATOR
Intervention: High-concentration contrast medium (HC-CM) with iopromide 370
Number of subjects: 65
Study 27631987 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid injection by physiotherapist
Number of subjects: 64
Study 27631987 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injection by orthopaedic surgeon
Number of subjects: 64
Study 23523130 — intervention group
Group type: EXPERIMENTAL
Intervention: CM+CBT
Number of subjects: 82
Study 23523130 — intervention group
Group type: EXPERIMENTAL
Intervention: CM
Number of subjects: 82
Study 23523130 — intervention group
Group type: COMPARATOR
Intervention: CBT
Number of subjects: 82
Study 21148046 — intervention group
Group type: EXPERIMENTAL
Intervention: Honey (2 × 20 g/d)
Number of subjects: 20
Study 21148046 — intervention group
Group type: COMPARATOR
Intervention: Artificial honey (2 × 20 g/d)
Number of subjects: 20
Study 19220941 — intervention group
Group type: EXPERIMENTAL
Intervention: Procedure-specific consent forms (PSCF)
Number of subjects: 100
Study 19220941 — intervention group
Group type: COMPARATOR
Intervention: Conventional consent forms
Number of subjects: 100
Study 17482078 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral distalization with a modified pendulum appliance
Number of subjects: 15
Study 15273582 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral metronidazole with paper diary
Number of subjects: 71
Study 15273582 — intervention group
Group type: COMPARATOR
Intervention: Oral metronidazole with PDA
Number of subjects: 71
Study 15273582 — intervention group
Group type: COMPARATOR
Intervention: PDA versus paper diary compliance agreement
Number of subjects: 71
Study 11520717 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF-DPI) 50 microg, twice daily
Number of subjects: 12
Study 11520717 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF-DPI) 100 microg, twice daily
Number of subjects: 12
Study 11520717 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate (MF-DPI) 400 microg, twice daily
Number of subjects: 12
Study 11520717 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9817274 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 36
Study 9817274 — intervention group
Group type: COMPARATOR
Intervention: CT
Number of subjects: 36
Study 7840022 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologically standardized extract of mites (active therapy)
Number of subjects: 58
Study 7840022 — intervention group
Group type: COMPARATOR
Intervention: Saline buffered solution (placebo)
Number of subjects: 58
Study 3042932 — intervention group
Group type: EXPERIMENTAL
Intervention: Detailed discussion with the patient's physician about decision making and life support therapy in the event of extreme or incapacitating illness.
Number of subjects: 74
Study 30653978 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin therapy
Number of subjects: 1982
Study 30653978 — intervention group
Group type: COMPARATOR
Intervention: No Metformin therapy
Number of subjects: 1982
Study 28807189 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives for couples' HIV testing and counselling (CHTC) - participants could select one of three grocery items worth US$1.50.
Number of subjects: 24679
Study 28807189 — intervention group
Group type: COMPARATOR
Intervention: Standard mobilisation for testing (comparison group).
Number of subjects: 24679
Study 28807189 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentives for CHTC.
Number of subjects: 24679
Study 28807189 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone survey post-CHTC.
Number of subjects: 24679
Study 26272712 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertebroplasty (VP)
Number of subjects: 78
Study 26272712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 23377836 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent physical activity (5 min every 30 min, 17 times)
Number of subjects: 9
Study 23377836 — intervention group
Group type: COMPARATOR
Intervention: Continuous physical activity (40 min and then 45 min)
Number of subjects: 9
Study 21943403 — intervention group
Group type: EXPERIMENTAL
Intervention: Home relapse management
Number of subjects: 138
Study 21943403 — intervention group
Group type: COMPARATOR
Intervention: Hospital relapse management
Number of subjects: 138
Study 18430270 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 1600
Study 18430270 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1600
Study 21519230 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk quantification model for 30-day postoperative mortality
Number of subjects: 635265
Study 21519230 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk quantification model for 30-day postoperative morbidity
Number of subjects: 635265
Study 15375668 — intervention group
Group type: EXPERIMENTAL
Intervention: Gentamycin collagen sponge (GRM(+))
Number of subjects: 229
Study 15375668 — intervention group
Group type: COMPARATOR
Intervention: Control group (GRM(-))
Number of subjects: 229
Study 11855540 — intervention group
Group type: COMPARATOR
Intervention: 20 mg omeprazole at 08:00 hr followed by placebo
Number of subjects: 16
Study 11855540 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg ranitidine at 22:00 hr
Number of subjects: 16
Study 11855540 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg omeprazole at 22:00 hr
Number of subjects: 16
Study 9665596 — intervention group
Group type: EXPERIMENTAL
Intervention: Riluzole 50 mg bid for 3 weeks
Number of subjects: 23
Study 9665596 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 23
Study 9665596 — intervention group
Group type: COMPARATOR
Intervention: Comparison of treated vs untreated
Number of subjects: 23
Study 7647826 — intervention group
Group type: EXPERIMENTAL
Intervention: Plantago ovata preparation (20 g granules with 200 ml water)
Number of subjects: 17
Study 7647826 — intervention group
Group type: COMPARATOR
Intervention: Placebo (20 g granules with 200 ml water)
Number of subjects: 17
Study 7647826 — intervention group
Group type: COMPARATOR
Intervention: Water (200 ml)
Number of subjects: 17
Study 2772857 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine posture for four hours
Number of subjects: 9
Study 2772857 — intervention group
Group type: COMPARATOR
Intervention: Sitting upright for four hours
Number of subjects: 9
Study 325342 — intervention group
Group type: EXPERIMENTAL
Intervention: delta9-tetrahydrocannabinol (THC) 15 MG/70 KG
Number of subjects: 15
Study 325342 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol 0-54 g/kg
Number of subjects: 15
Study 325342 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of THC and Ethanol
Number of subjects: 15
Study 29993259 — intervention group
Group type: EXPERIMENTAL
Intervention: Jidabokuippo (JDI) 7.5 g
Number of subjects: 0
Study 29993259 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 0
Study 27311074 — intervention group
Group type: EXPERIMENTAL
Intervention: Lundborg's method
Number of subjects: 38
Study 27311074 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirotakova's method
Number of subjects: 38
Study 24114079 — intervention group
Group type: EXPERIMENTAL
Intervention: End-tidal-controlled anaesthesia (EtCA)
Number of subjects: 80
Study 24114079 — intervention group
Group type: COMPARATOR
Intervention: Manually-controlled anaesthesia (MCA)
Number of subjects: 80
Study 21933201 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate
Number of subjects: 30
Study 20391509 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 60 mg
Number of subjects: 227
Study 20391509 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab 180 mg
Number of subjects: 227
Study 20391509 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 18482303 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial fall prevention program (staff and resident education, environmental adaptations, hip protectors, balance and resistance training)
Number of subjects: 725
Study 18482303 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial fall prevention program
Number of subjects: 725
Study 15835228 — intervention group
Group type: EXPERIMENTAL
Intervention: pH-balanced cleanser
Number of subjects: 0
Study 15835228 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 0
Study 12627404 — intervention group
Group type: COMPARATOR
Intervention: Various doses of a drug
Number of subjects: 0
Study 10390007 — intervention group
Group type: EXPERIMENTAL
Intervention: ECF regimen (epirubicin, cisplatin, and protracted venous infusion fluorouracil)
Number of subjects: 274
Study 10390007 — intervention group
Group type: COMPARATOR
Intervention: FAMTX (5‐FU, doxorubicin, and methotrexate)
Number of subjects: 274
Study 8735024 — intervention group
Group type: EXPERIMENTAL
Intervention: ProtoVIEW (computer-based protocol consultation)
Number of subjects: 8
Study 8735024 — intervention group
Group type: COMPARATOR
Intervention: Paper-based protocol consultation (control)
Number of subjects: 8
Study 2006742 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of 0.25% bupivacaine at 0.125 mL.kg‐1.h‐1 (n = 13)
Number of subjects: 25
Study 2006742 — intervention group
Group type: COMPARATOR
Intervention: Repeated bolus injections of 0.5% bupivacaine with epinephrine 1:200,000 at 0.4 mL/kg every sixth hour (n = 12)
Number of subjects: 25
Study 7331659 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass surgery with a 3:1 jejunal to ileal ratio
Number of subjects: 13
Study 7331659 — intervention group
Group type: COMPARATOR
Intervention: Jejunoileal bypass surgery with a 1:3 jejunal to ileal ratio
Number of subjects: 13
Study 7331659 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-surgery (both groups)
Number of subjects: 13
Study 31165721 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Reality (VR) training
Number of subjects: 28
Study 31165721 — intervention group
Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 28
Study 30026567 — intervention group
Group type: EXPERIMENTAL
Intervention: Multispecies probiotic
Number of subjects: 0
Study 30026567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26297325 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g kg(‐1))
Number of subjects: 11
Study 26297325 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (0.2 g kg(‐1))
Number of subjects: 11
Study 25271389 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral nutritional support
Number of subjects: 2400
Study 25271389 — intervention group
Group type: COMPARATOR
Intervention: Enteral nutritional support
Number of subjects: 2400
Study 22002790 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurofeedback (NFB) protocol with reward (tone of 1000 Hz) when theta AP was reduced
Number of subjects: 14
Study 22002790 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (random administration of the same tone)
Number of subjects: 14
Study 20080034 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose (HD) group: loading dose of selenium as selenite 15.18 micromol over 2 h and thereafter 10.12 micromol/d as a continuous intravenous infusion (CIV) for 10 d
Number of subjects: 20
Study 20080034 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-high-dose (VHD) group: loading dose of 25.30 micromol over 2 h and thereafter 20.24 micromol as a CIV for 10 d
Number of subjects: 20
Study 20080034 — intervention group
Group type: COMPARATOR
Intervention: Both groups (HD and VHD)
Number of subjects: 20
Study 18645551 — intervention group
Group type: EXPERIMENTAL
Intervention: Prosthetic hernia repair (gold standard)
Number of subjects: 0
Study 18645551 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic approach
Number of subjects: 0
Study 18645551 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 0
Study 16126048 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic mixture (Bifidobacteria infantis, Streptococcus thermophilus, and Bifidobacteria bifidus; Solgar, Israel) 10(9) CFU/day
Number of subjects: 145
Study 16126048 — intervention group
Group type: COMPARATOR
Intervention: Control (no feed supplements)
Number of subjects: 145
Study 12385860 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (2 mg) for 28 days
Number of subjects: 16
Study 12385860 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (2 mg) for 14 days and dydrogesterone (10 mg) for 14 days
Number of subjects: 16
Study 12385860 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 16
Study 12219057 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal ventilation (PCO(2) target >52 mm Hg)
Number of subjects: 220
Study 12219057 — intervention group
Group type: COMPARATOR
Intervention: Routine ventilation (PCO(2) target <48 mm Hg)
Number of subjects: 220
Study 18370539 — intervention group
Group type: EXPERIMENTAL
Intervention: Imiquimod 1% cream
Number of subjects: 60
Study 18370539 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 8077707 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV vaccine containing 10 micrograms of S
Number of subjects: 282
Study 8077707 — intervention group
Group type: EXPERIMENTAL
Intervention: PreS2 + S vaccines (2 + 10 micrograms, 4 + 20 micrograms, or 8 + 40 micrograms)
Number of subjects: 282
Study 2809024 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (IT) with MC extract
Number of subjects: 51
Study 736777 — intervention group
Group type: EXPERIMENTAL
Intervention: Short hepatic inflow occlusion (7 +/- 2 minutes)
Number of subjects: 20
Study 736777 — intervention group
Group type: COMPARATOR
Intervention: Complete hepatic vascular exclusion with prolonged warm liver ischemia (38 +/- 5 minutes)
Number of subjects: 20
Study 30327875 — intervention group
Group type: EXPERIMENTAL
Intervention: Eradication therapy for H. pylori-positive gastric low-grade MALT lymphoma
Number of subjects: 102
Study 30327875 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation therapy with 25.2 Gy
Number of subjects: 102
Study 30327875 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy with 36 Gy
Number of subjects: 102
Study 30327875 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of t(11,18) translocation
Number of subjects: 102
Study 30327875 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonality of the tumour cells
Number of subjects: 102
Study 27978771 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine plus medical management
Number of subjects: 0
Study 27978771 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific behavioral interventions (primarily contingency management)
Number of subjects: 0
Study 27978771 — intervention group
Group type: COMPARATOR
Intervention: High-quality medical management
Number of subjects: 0
Study 27978771 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped-care model
Number of subjects: 0
Study 27978771 — intervention group
Group type: EXPERIMENTAL
Intervention: Retention strategies in buprenorphine treatment
Number of subjects: 0